FINAL STUDY REPORT

PROTOCOL TITLE

Residual Self-Sanitizing Efficacy

PRODUCT IDENTITY

2ADPHQ-03701J

DATA REQUIREMENTS

U.S. EPA 40 CFR Part 158
"Data Requirements for Registration"
Pesticide Assessment Guidelines - Subdivision G, 91-2 (m)

PROJECT NUMBER

10524

PROTOCOL NUMBER

ALP08020501.RES

AUTHOR

Brad K. Onstad, B.S.
Study Director
Chemcial Germicide Testing Services

STUDY COMPLETION DATE

April 6, 2001

PERFORMING LABORATORY

ViroMed Biosafety Laboratories 6101 Blue Circle Drive Minneapolis, MN 55343

SPONSOR

Alphamed Pharmaceuticals 1409 N. Fort Harrison Avenue Suite A Clearwater, FL 33755



Alphamed Pharmaceuticals Project No. 10524 Page 2 of 14

STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10 (d) (1) (A), (B), or (C).

Company:	Alphamed Pharmaceuticals		
C		Deter	
Company Agent:		Date:	



Alphamed Pharmaceuticals Project No. 10524 Page 3 of 14

GOOD LABORATORY PRACTICE STATEMENT

The study referenced in this report was conducted in compliance with U.S. Environmental Protection Agency Good Laboratory Practice (GLP) regulations set forth in 40 CFR Part 160.

The studies not performed by or under the direction of ViroMed Laboratories, Inc. are exempt from this Good Laboratory Practice Statement and include: characterization and stability of the compound(s).

Submitter:	Date:
Sponsor:	Date:
Study Director: Rul Classes Brad K. Onstad, B.S.	Date: 4/6/01

Alphamed Pharmaceuticals Project No. 10524 Page 4 of 14

QUALITY ASSURANCE UNIT SUMMARY

Study: Residual Self-Sanitizing Efficacy

The objective of the Quality Assurance Unit is to monitor the conduct and reporting of nonclinical laboratory studies. These studies have been performed under Good Laboratory Practice regulations (40 CFR Part 160) and in accordance to standard operating procedures and standard protocols. The Quality Assurance Unit maintains copies of study protocols and standard operating procedures and has inspected this study on the date(s) listed below. Studies are inspected at time intervals to assure the integrity of the study. The findings of these inspections have been reported to management and the Study Director.

Phase Inspected	Date	Study Director Review	Management Review	
Critical Phase	February 27, 2001	February 27, 2001	1 11 6 2001	
Final Report	April 4, 2001	April 4, 2001	April 6, 2001	

Documentation of the above Quality Assurance audits have been reviewed.

Quality Assurance Auditor: Kachelle L. Tornson

Date: 04/06/01

Alphamed Pharmaceuticals Project No. 10524 Page 5 of 14

TABLE OF CONTENTS

Title Page
Statement of No Data Confidentiality Claims
Good Laboratory Practice Statement
Quality Assurance Unit Summary
Table of Contents
Study Personnel 6
General Study Information
Test Substance Identity
Study Dates
Objective
Study Materials
Test Method
Test Controls
Study Acceptance Criteria
Protocol Changes
Data Analysis
Study Retention
Results
Analysis
Study Conclusion
Tables 1-4
Tables 5-6



Alphamed Pharmaceuticals Project No. 10524 Page 6 of 14

STUDY PERSONNEL

STUDY DIRECTOR: Brad K. Onstad, B.S.

Professional personnel involved:

Bonita L. Baskin, Ph.D.

Karen M. Ramm, B.A.

Brad K. Onstad, B.S.

Adam W. Pitt, B.S.

Travis M. Roth, B.A.

Kristine E. Roth

Josh P. Magnusson

- Laboratory Director
- Division Director
- Laboratory Supervisor
- Research Assistant I
- Research Assistant I
- Research Assistant I
- Research Assistant I

Alphamed Pharmaceuticals Project No. 10524 Page 7 of 14

STUDY REPORT

GENERAL STUDY INFORMATION

Study Title: Residual Self-Sanitizing Efficacy

Project Number: 10524

Protocol Number: ALP08020501.RES

Sponsor: Alphamed Pharmaceuticals

1409 N. Fort Harrison Avenue Suite A

Clearwater, FL 33755

Test Facility: ViroMed Biosafety Laboratories

6101 Blue Circle Drive Minneapolis, MN 55343

TEST SUBSTANCE IDENTITY

Test Substance Name: 2ADPHQ-03701J

Test Substance Characterization

Test substance characterization as to content, stability, etc., (40 CFR, Part 160, Subpart F [160.105]) is the responsibility of the Sponsor.

STUDY DATES

Date Sample Received:
Study Initiation Date:
Experimental Start Date:
Experimental End Date:
Study Completion Date:
February 19, 2001
February 16, 2001
February 26, 2001
March 7, 2001
April 6, 2001

OBJECTIVE

The objective of this study was to determine the "Residual Self-Sanitizing Activity" of the Sponsor's test material.

Alphamed Pharmaceuticals Project No. 10524 Page 8 of 14

STUDY MATERIALS

Test System/Growth Media

Test Organism	ATCC#	Growth Medium	Incubation Parameters
Salmonella choleraesuis	10708	AOAC Synthetic Broth	35-37°C, aerobic

The microorganism used in this study was obtained from the American Type Culture Collection, Manassas, Virginia.

Recovery Media

Neutralizing Subculture Medium: Letheen Broth

Agar Plate Medium: Tryptic Soy Agar with 5% sheep blood (BAP)

Reagents

Organic Soil Load Description: No organic soil was required

TEST METHOD

Carriers

Approximately 75mm x 25mm glass slides were placed in glass petri dishes and sterilized in an air oven for 2 hours at approximately 180°C. Individual sterile plastic petri dishes were matted with 9 cm filter paper. One sterile glass slide was transferred into each of the matted petri dishes.

Medication

The carriers were allowed to equilibrate to ambient temperature prior to medication. Each carrier was then treated with the test substance in the manner specified by the Sponsor. The spray bottle was held 4-6 inches from the carrier. The surface was sprayed for 3 seconds at which point the carriers were completely wet. A timer was started for the holding period.

Holding Periods

The petri dishes containing the treated carriers were held at room temperature with their lids ajar for the Sponsor specified 24 hour, 72 hour and 7 day holding periods.

Preparation of Test Organism

A 0.5 McFarland turbidity suspension was prepared in Butterfield's Buffer using a stock culture of the test organism. A lawn of growth was prepared by adding 0.2 mL of this suspension to agar plates and incubating 48 ± 4 hours at 35-37°C. A 3 mL aliquot of Butterfield's Buffer was transferred to each agar plate and cell swabbed to suspend the organisms. The suspension was filtered through sterile gauze and diluted to a 0.5 McFarland turbidity standard. Prior to use in testing procedures, the suspension was Vortex mixed and a 1:50 dilution in Butterfield's Buffer was made.

Carrier Contamination

After the specified holding times, 0.01 mL of the test organism suspension was added to the designated areas of separate replicates of previously treated carriers at staggered intervals. The test organisms were allowed to contact the product residue for a 15 minute exposure time at ambient temperature (21-22°C).

Alphamed Pharmaceuticals Project No. 10524 Page 9 of 14

Subculture

Following the 15 minute exposure period, each carrier was transferred at identical staggered intervals to 40 mL of Letheen Broth and vortex mixed. The number of survivors from each carrier was determined by a standard spread plate method done on the above and/or serial dilutions thereof, using TSA containing 5% Sheep Blood (BAP).

Incubation and Observation

All subculture plates and jars were incubated for 48 ± 4 hours at $35-37^{\circ}$ C. Following incubation, the subculture plates and jars were visually examined for growth. The colonies present on each plate were counted and recorded and the number of Colony Forming Units present on each carrier or in each suspension was calculated. Representative subculture plates demonstrating growth were confirmed to be the test organisms.

TEST CONTROLS

Numbers Control

The test procedure was performed as described using three sterile untreated carriers. The carriers were held for the appropriate holding periods, inoculated and held for the identical exposure period and subcultured in an identical manner to the test carriers. The subculture suspension was serially diluted and plated using standard microbiological techniques. Following incubation, the organism plates were observed to enumerate the concentration of the test organism present at the time of testing.

Initial Suspension Population Control

The number of microbes present in the initial suspension used in the contamination procedure was determined by a standard spread plate count procedure using agar identical to the test procedure

Purity Control

A "streak plate for isolation" was performed on the organism culture and following incubation examined in order to demonstrate a pure culture.

Carrier Sterility Control

A representative sterile carrier was added to the subculture media, incubated, and observed for lack of growth to confirm sterility.

Media Sterility Control

Uninoculated subculture medium was incubated and observed for lack of growth to confirm sterility.

Viability Control

The viability of a representative inoculated carrier of the test organism was confirmed by subculture.

Alphamed Pharmaceuticals Project No. 10524 Page 10 of 14

Neutralization Confirmation

The neutralization of the test substance was confirmed by exposing sterile carriers to the test substance and transferring them to 40 mL of neutralizing broth. The neutralization jar was inoculated with 1.0 mL of an organism suspension containing low levels of organism, held for five minutes and 1.0 mL was plated in duplicate to the appropriate subculture medium.

A numbers control not containing the test material was also included and compared to the test, in which a sterile carrier was transferred to 40 mL of neutralizing broth. The neutralization jar was inoculated with 1.0 mL of an organism suspension containing low levels of organism, held for five minutes and 1.0 mL was plated in duplicate to the appropriate subculture medium.

STUDY ACCEPTANCE CRITERIA

Test Substance Performance Criteria

The EPA requires the results to show a bacterial reduction of at least 99.9% over the parallel control.

Control Acceptance Criteria

The study controls performed according to acceptance criteria.

PROTOCOL CHANGES

Protocol Amendments: No protocol amendments were required for this study.

Protocol Deviations: No protocol deviations occurred during this study.

Alphamed Pharmaceuticals Project No. 10524 Page 11 of 14

DATA ANALYSIS

Calculations

The colonies present on each plate were counted and recorded and the number of CFU present on each carrier or in each suspension was calculated.

- 1. CFU/Carrier = CFU (Average of Plates) x Dilution Factor x Volume of Neutralizing Broth
 Number of Carriers to be Tested x Volume Plated
- 2. Geometric Mean of Number of Organisms Surviving on Control Carriers:

The geometric mean of the number of organisms surviving on the three inoculated control carriers was determined by the following equation:

Geometric Mean =
$$\frac{\text{Antilog of } \text{Log}_{10} \text{X}_1 + \text{Log}_{10} \text{X}_2 + \text{Log}_{10} \text{X}_3}{3}$$

where X equals number of organisms surviving per control carrier.

An average of at least 4.0×10^4 organisms must have survived on the inoculated control carriers for the test to be valid.

3. Geometric Mean of Number of Organisms Surviving on Test Carriers:

The geometric mean of the number of organisms surviving on the test carriers was determied by the following equation:

Geometric Mean =
$$\frac{\text{Antilog of Log}_{10}Y_1 + \text{Log}_{10}Y_2 + \text{Log}_{10}Y_3}{3}$$

where Y equals number of organisms surviving per test carrier.

4. Percent Reduction: The following equation was used to calculate percent reduction:

% reduction =
$$[(a - b)/a] \times 100$$

where: a = geometric mean of the number of organisms surviving on the control carriers b = geometric mean of the number of organisms surviving on the test carriers.

Statistical Analysis

None used.

Alphamed Pharmaceuticals Project No. 10524 Page 12 of 14

STUDY RETENTION

Record Retention

All of the original raw data developed exclusively for this study shall be archived at ViroMed Laboratories, 2540 Executive Drive, St. Paul, MN 55120. These original data include, but are not limited to, the following:

- 1. Certified copy of final study report.
- 2. Original signed protocol.
- 3. Any protocol amendments.
- 4. All handwritten raw data for control and test substances including, but not limited to notebooks, data forms and calculations.
- 5. All measured data used in formulating the final report.
- 6. Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.

Test Substance Retention

The test substance will be discarded following study completion per Sponsor approved protocol. It is the responsibility of the Sponsor to retain a sample of the test material.

RESULTS

Control and Neutralization Results (Tables 1-3, 5)

All data measurements/controls including the numbers, viability, carrier sterility, neutralization confirmation, culture purity and media sterility controls were within acceptance criteria.

Test Results (Tables 4 and 6)

ANALYSIS

2ADPHQ-03701J, ready to use, demonstrated >99.999% reduction of *Salmonella choleraesuis* following a 24 hour hold, a ≥99.999% reduction of *Salmonella choleraesuis* following a 72 hour hold, and a >99.999% reduction of *Salmonella choleraesuis* following a 7 day hold with a 15 minute contact period.

STUDY CONCLUSION

Under the conditions of this investigation, 2ADPHQ-03701J, ready to use, is an effective residual sanitizer against *Salmonella choleraesuis* for hard nonporus surfaces after a 24 hour, 72 hour and 7 day hold with a 15 minute contact period.

In the opinion of the Study Director, there were no circumstances that may have adversely affected the quality or integrity of the data.

Alphamed Pharmaceuticals Project No. 10524 Page 13 of 14

TABLE 1: CONTROL RESULTS

T	Result			
Type of Control	24 Hour Hold	72 Hour Hold	7 day Hold	
Culture Purity	Pure	Pure	Pure	
Viability Control	Growth	Growth	Growth	
Media Sterility Control	No Growth	No Growth	No Growth	
Carrier Sterility Control	No Growth	No Growth	No Growth	

TABLE 2: NEUTRALIZATION CONFIRMATION CONTROL RESULTS (CFU)

Test Substance	24 hour	72 hour	7 day
2ADPHQ-03701J	37, 57	5,3	5, 8
Numbers Control	60, 52	5,4	10,7

The neutralization controls demonstrated sufficient growth, eliminating bacteriostasis as a cause of lack of growth in the test system.

TABLE 3: INITIAL SUSPENSION RESULTS (CFU/mL)

Test Organism	24 hour	72 hour	7 day
S. choleraesuis	1.1 x 10 ⁸	8.0×10^6	1.36×10^7

TABLE 4: EVALUATION OF TEST CARRIER DATA (CFU/CARRIER)

Test Organism	Campian #			
	Carrier #	24 hour	72 hour	7 day
S. choleraesuis	1	< 1	< 40	< 1
	2	< 1	< 1	< 1
	.3	< 1	< 1	< 1
	Average	< 1	< 14	< 1

Alphamed Pharmaceuticals Project No. 10524 Page 14 of 14

TABLE 5: EVALUATION OF NUMBERS CONTROL CARRIER DATA (CFU/CARRIER)

Test Organism	Test	C . "	Residual Holding Period			
	Carrier#	24 hour	72 hour	7 day		
S. choleraesuis	1	2.9 x 10 ⁵	4.38 x 10 ⁵	3.6 x 10 ⁵		
	2	3.4 x 10 ⁵	3.3 x 10 ⁵	3.3 x 10 ⁵		
	3	3.9 x 10 ⁵	4.40 x 10 ⁵	3.4 x 10 ⁵		
	Average	3.4 x 10 ⁵	4.0 x 10 ⁵	3.4 x 10 ⁵		

TABLE 6: CALCULATED VALUES

Residual Holding Period	Control Log ₁₀ (Average)	Test Log ₁₀ (Average)	Control Geometric Mean (Average CFU/ Carrier)	Test Geometric Mean (Average CFU/ Carrier)	% Reduction
24 Hour	5.528	0	3.4 x 10 ⁵	1	>99.999
72 Hour	5.601	0.534	4.0 x 10 ⁵	3.4	≥99.999
7 Day	5.535	0	3.4 x 10 ⁵	1	>99.999

The use of the ViroMed name, logo or any other representation of ViroMed without the written approval of ViroMed is prohibited. In addition, ViroMed may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express written permission of ViroMed Laboratories, Inc.